The clinical outcomes of rituximab biosimilar CT-P10 (Truxima^®) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experience

Abstract

We evaluated real-world effectiveness and safety of CT-P10 (Truxima^®) compared with originator rituximab in diffuse large B-cell lymphoma (DLBCL) treatment. Before and after the introduction of CT-P10 to our institute (November 2017), 221 newly-diagnosed DLBCL patients received rituximab with standard cyclophosphamide, vincristine, doxorubicin and prednisone. Patients received originator rituximab throughout (n = 95), switched from originator rituximab to CT-P10 (n = 36), or received CT-P10 throughout (n = 90). There were no significant differences between groups in overall response rate (91.6% vs 94.4% vs 96.7%, respectively; p = 0.403) or complete response rate (84.2% vs 77.8% vs 86.7%, respectively; p = 0.467). Kaplan–Meier survival curves also showed no significant differences in progression-free survival and overall survival between groups (log-rank p = 0.794 and p = 0.955, respectively). Safety profiles were comparable between treatment groups. These data support the ability of CT-P10 to successfully replace originator rituximab in DLBCL treatment and, given the lowered financial barrier, to improve the overall prognosis for DLBCL patients.

Keywords:

• Diffuse large B-cell lymphoma
• biosimilar
• rituximab
• CT-P10
• Truxima^®
• real-world evidence

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability

The authors confirm that the data supporting the findings of this study are available within the article.

Additional information

Funding

This research was funded by the National Research Foundation of Korea, grant numbers MSIP; 2019R1H1A1080141 awarded to Y.S.L. Medical editing support (including copyediting) was provided by Beatrice Tyrrell, DPhil at Aspire Scientific (Bollington, UK) and funded by Celltrion Healthcare Co., Ltd (Incheon, Republic of Korea).